Researchers have revealed a novel association between chromosome 18q deletion syndrome and late-onset combined immunodeficiency (LOCID). Their finding challenges the previously held notion that 18q ...
The product is expected to be available in early 2026. The Food and Drug Administration (FDA) has approved Qivigy (immune globulin intravenous [IV], human-kthm) 10% solution for the treatment of ...
Alyglo is manufactured using cation exchange chromatography, which reduces coagulation factor XIa to undetectable levels. Alyglo ™ (immune globulin intravenous, human-stwk) 10% liquid is now available ...
Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Please provide your email address to receive an email when new articles are posted on . The conference will focus on clinical care, including diagnosis and treatment. The agenda was designed for ...
Tokyo Medical and Dental University (TMDU) researchers have discovered that patients with 18q deletion syndrome can experience both cellular and humoral immunodeficiency Tokyo, Japan – Chromosome 18q ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results